Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours
Authors
Keywords
FDG PET, Neuroendocrine tumours, PRRT, <sup>177</sup>Lu-DOTATATE
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 40, Issue 6, Pages 881-888
Publisher
Springer Nature
Online
2013-02-26
DOI
10.1007/s00259-013-2369-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment with the Radiolabelled Somatostatin Analog177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
- (2013) Maddalena Sansovini et al. NEUROENDOCRINOLOGY
- Neoadjuvant Downsizing by Internal Radiation
- (2011) Samer Ezziddin et al. CLINICAL NUCLEAR MEDICINE
- A new dimension of FDG-PET interpretation: assessment of tumor biology
- (2011) Thomas C. Kwee et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
- (2011) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Was ist neu?
- (2011) J. Lüttges PATHOLOGE
- Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas
- (2010) Nicola Fazio et al. CANCER TREATMENT REVIEWS
- 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors
- (2010) T. Binderup et al. CLINICAL CANCER RESEARCH
- Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters
- (2010) Martin B Niederle et al. ENDOCRINE-RELATED CANCER
- Novel Anticancer Agents in Clinical Trials for Well-Differentiated Neuroendocrine Tumors
- (2010) Sandrine Faivre et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy
- (2010) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging
- (2010) Emilio Bombardieri et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE
- (2010) Irene Virgolini et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors
- (2010) V. Ambrosini et al. JOURNAL OF NUCLEAR MEDICINE
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- (2009) Dik J Kwekkeboom et al. ENDOCRINE-RELATED CANCER
- Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors
- (2009) E. Garin et al. JOURNAL OF NUCLEAR MEDICINE
- Functional imaging of neuroendocrine tumors with combined PET/CT using68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and18F-FDG
- (2008) Irfan Kayani et al. CANCER
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
- (2008) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastroenteropancreatic neuroendocrine tumours
- (2008) Irvin M Modlin et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started